Cell Biotech Co (049960.KQ) Stock Price

Cell Biotech Co Price

CLOSED
14,080.00
​
Market closed

Revenue has compounded at 9.9% per year over the past 19 years to 53.13 B KRW. Earnings per share have grown at 22.3% per year over the last 19 years. Cell Biotech Co's net margin stands at 19.1%, down from 22.2% several years earlier. Cell Biotech Co currently offers a dividend yield of about 3.20%. The payout ratio is around 39% of earnings. The dividend has grown at 8.7% per year over the past 18 years.

Cell Biotech Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co business model & stock analysis

Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs.

Frequently asked questions about Cell Biotech Co

6 analysts currently rate the Cell Biotech Co stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the Cell Biotech Co share trades at 9.38 EUR (14,080.00 KRW).

The revenue cannot currently be calculated for Cell Biotech Co.

The profit cannot currently be calculated for Cell Biotech Co.

The P/E ratio cannot be calculated for Cell Biotech Co at the moment.

The P/S cannot be calculated for Cell Biotech Co currently.

The Eulerpool Quality Score for Cell Biotech Co is 3/10.

The ISIN of Cell Biotech Co is KR7049960008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cell Biotech Co is 049960.KQ. The ticker symbol is used to trade Cell Biotech Co shares on the stock exchange.

Fair ValueTerminal
14,502.40 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Dec 13, 2002
ISIN
KR7049960008
Cusip
Y1233N109
Market capitalization
96.36 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
12.18
P/B Ratio
0.73
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
7.69 %
Dividend
Dividend yield
3.20 %
Payout Ratio
38.89 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
22.00 %
Last updated Nov 11, 2026, 6:12 PM

Cell Biotech Co Peer Group

Cell Biotech Co FIGI

049960:KS · BBG000HL1CP9049960:KQ · BBG000HL1FD5

All fundamentals and in-depth analysis of Cell Biotech Co

Our stock analysis for Cell Biotech Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cell Biotech Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.